• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常、发育异常和肿瘤性巴雷特食管中p53蛋白的积累。

Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.

作者信息

Krishnadath K K, Tilanus H W, van Blankenstein M, Bosman F T, Mulder A H

机构信息

Department of Surgery, Erasmus University, Rotterdam, The Netherlands.

出版信息

J Pathol. 1995 Feb;175(2):175-80. doi: 10.1002/path.1711750204.

DOI:10.1002/path.1711750204
PMID:7738712
Abstract

Accumulation of p53 protein was determined by immunohistochemistry in archival material of biopsy specimens from 102 patients with Barrett's oesophagus with different grades of dysplasia, in 24 oesophageal adenocarcinomas associated with Barrett's oesophagus, and in 23 cases of metaplastic epithelium adjacent to these carcinomas. Immunostaining for the p53 protein was found in 23/102 (23 per cent) cases of the Barrett's oesophagus biopsies and in 12/23 (52 per cent) cases of Barrett's oesophagus adjacent to adenocarcinoma. Significant correlations were found between the grade of dysplasia and p53 immunoreactivity in both Barrett's biopsies without adenocarcinoma (P < 0.001) and Barrett's oesophagus adjacent to adenocarcinoma (P < 0.05). In the adenocarcinomas, intense nuclear immunohistochemical staining for p53 was diffusely or focally present in 20/24 (83 per cent) of the specimens. In Barrett's oesophagus, p53 is a progression marker with high expression in high-grade dysplasia (89 per cent) and adenocarcinoma (83 per cent).

摘要

采用免疫组织化学方法,对102例不同程度发育异常的巴雷特食管活检标本存档材料、24例与巴雷特食管相关的食管腺癌以及23例这些癌旁化生上皮病例进行p53蛋白蓄积情况的检测。在巴雷特食管活检标本中,23/102例(23%)检测到p53蛋白免疫染色阳性;在腺癌旁的巴雷特食管中,12/23例(52%)检测到阳性。在无腺癌的巴雷特食管活检标本(P < 0.001)以及腺癌旁的巴雷特食管(P < 0.05)中,发育异常程度与p53免疫反应性之间均存在显著相关性。在腺癌标本中,20/24例(83%)出现p53蛋白强烈的核免疫组化染色,呈弥漫性或局灶性。在巴雷特食管中 p53是一种进展标志物,在高级别发育异常(89%)和腺癌(83%)中高表达。

相似文献

1
Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.正常、发育异常和肿瘤性巴雷特食管中p53蛋白的积累。
J Pathol. 1995 Feb;175(2):175-80. doi: 10.1002/path.1711750204.
2
p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.巴雷特食管肿瘤进展过程中的p53基因突变与蛋白积聚
Mod Pathol. 2001 May;14(5):397-403. doi: 10.1038/modpathol.3880324.
3
p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.使用抗体DO-7检测p53在巴雷特食管、发育异常及腺癌中的表达。
J Pathol. 1994 Jul;173(3):221-6. doi: 10.1002/path.1711730304.
4
Molecular evaluation of ablative therapy of Barrett's oesophagus.巴雷特食管消融治疗的分子评估
J Pathol. 2005 Jan;205(1):57-64. doi: 10.1002/path.1685.
5
High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.巴雷特食管中的高级别异型增生和浅表腺癌:组织学定位及p53、p21和Bcl-2癌蛋白的表达
Virchows Arch. 2003 Jan;442(1):18-24. doi: 10.1007/s00428-002-0674-1. Epub 2002 Sep 24.
6
Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.利用蔗糖酶异麦芽糖酶和p53检测贲门巴雷特腺癌
Ann Thorac Surg. 1996 Nov;62(5):1460-5; discussion 1465-6. doi: 10.1016/0003-4975(96)00749-7.
7
Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.通过DNA原位杂交和免疫组织化学检测巴雷特腺癌和巴雷特食管中的基因变化。
Cytometry. 1994 Feb 1;15(2):176-84. doi: 10.1002/cyto.990150212.
8
Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus.巴雷特食管刷检及活检中p53核蛋白积聚的检测
Cancer Detect Prev. 1997;21(4):326-31.
9
Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.核p53表达在巴雷特食管监测中的诊断意义——一项纵向研究
Z Gastroenterol. 1999 Oct;37(10):1005-11.
10
Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.转化生长因子-α、表皮生长因子受体及MiB-1在巴雷特相关肿瘤中的表达:与预后的相关性
Mod Pathol. 1997 Feb;10(2):105-12.

引用本文的文献

1
p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.p53蛋白积聚可预测巴雷特化生的恶性进展:一项对275例患者的前瞻性研究。
Histopathology. 2017 Jul;71(1):27-33. doi: 10.1111/his.13193. Epub 2017 Apr 11.
2
Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas.综合分子分析揭示食管腺癌中基因组和表观基因组改变之间的复杂相互作用。
Sci Rep. 2017 Jan 19;7:40729. doi: 10.1038/srep40729.
3
Cell culture models for studying the development of Barrett's esophagus: a systematic review.
用于研究巴雷特食管发育的细胞培养模型:系统评价。
Cell Oncol (Dordr). 2012 Jun;35(3):149-61. doi: 10.1007/s13402-012-0076-6. Epub 2012 Apr 3.
4
Predicting Neoplastic Progression in Barrett's Esophagus.预测巴雷特食管的肿瘤进展
Ann Gastroentol Hepatol. 2010 Jun;1(1):1-10.
5
Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus.生物标志物在不完全消融的巴雷特食管中的异常表达。
Ann Surg. 2006 Dec;244(6):1031-6. doi: 10.1097/01.sla.0000224913.19922.7e.
6
Barrett's oesophagus and adenocarcinoma.巴雷特食管与腺癌。
World J Surg Oncol. 2004 May 7;2:12. doi: 10.1186/1477-7819-2-12.
7
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.贲门腺癌与远端食管癌中环氧化酶2表达的比较。
Gut. 2003 Dec;52(12):1678-83. doi: 10.1136/gut.52.12.1678.
8
Barrett's esophagus: model of neoplastic progression.巴雷特食管:肿瘤进展模型
World J Surg. 2003 Sep;27(9):1009-13. doi: 10.1007/s00268-003-7053-1. Epub 2003 Aug 18.
9
Observer variation in the diagnosis of superficial oesophageal adenocarcinoma.浅表性食管腺癌诊断中的观察者差异
Gut. 2002 Nov;51(5):671-6. doi: 10.1136/gut.51.5.671.
10
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.巴雷特食管进展的预测因素II:基线17p(p53)杂合性缺失可识别肿瘤进展风险增加的患者亚组。
Am J Gastroenterol. 2001 Oct;96(10):2839-48. doi: 10.1111/j.1572-0241.2001.04236.x.